| Description |
UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey[1]. UK-101 induces cell apoptosis and can be used for the study of prostate cancer[2].
|
| Related Catalog |
|
| Target |
IC50: 104 nM (LMP2) IC50: 15 μM (immunoproteasome β1c) IC50: 1 μM (immunoproteasome β5)[1]
|
| In Vitro |
UK-101 (2-8 μM; 24 hours) induces cell cycle arrest and increases the number of the PC-3 cells arrest in G1 phase of the cell cycle[2]. UK-101 (2-8 μM; 24 hours) induces cell apoptosis, shows a minimal increase in late apoptosis, but has no significant increase in early apoptosis[2]. UK-101 (1-8 μM; 24 hours) induces cells accumulation in the G1 phase of the cell cycle, it increases p27 accumulation and significantly increases PARP cleavage as a dose-dependent manner[2]. Cell Cycle Analysis[1] Cell Line: PC-3 cells Concentration: 2 μM; 8 μM Incubation Time: 24 hours Result: Induced G1 cell cycle arrest in PC-3 cells. Apoptosis Analysis[1] Cell Line: PC-3 cells Concentration: 2 μM; 8 μM Incubation Time: 24 hours Result: Increased cell apoptosis as a dose-dependent manner. Western Blot Analysis[1] Cell Line: PC-3 cells Concentration: 1 μM; 2 μM; 8 μM Incubation Time: 24 hours Result: Increased PARP cleavage and p27 accumulation as a dose-dependent manner.
|
| In Vivo |
UK-101 (intraperitoneal injection; 1-3 mg/kg; twice a week; 3 weeks) decreases tumor volume as a dose-dependent manner, it significantly decreases tumor volume at a dose of 3 mg/kg. Additionally, UK-101-treated mice is suffering less systemic toxicity and the weights of mice treated with UK-101 remains steady over the 3-week treatment period[2]. Animal Model: Subcutaneously implanted PC-3 cells in 6-week-old male BALB/c athymic nude mice[2] Dosage: 1 mg/kg; 3 mg/kg Administration: Intraperitoneal injection; twice a week; 3 weeks Result: Inhibited tumour growth in the prostate cancer mouse xenograft model.
|
| References |
[1]. de Bruin G, et al. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem. 2014 Jul 24;57(14):6197-209. [2]. Wehenkel M, et al. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer. 2012 Jun 26;107(1):53-62.
|
